code,parent_code,name,medical_reasoning
"3A03.0,3A03,Hereditary orotic aciduria",,,"Key signals for hereditary orotic aciduria, such as orotic acid levels in urine or specific genetic markers, are not available in the listed features."
"3A03.3,3A03,Copper deficiency anaemia",,,"Key signals for screening copper deficiency anemia, such as serum copper levels and ceruloplasmin, are missing from the available features."
"3A03.5,3A03,Acquired vitamin A deficiency anaemia",,,"Key signals for assessing vitamin A deficiency anemia, such as serum retinol levels or dietary intake of vitamin A, are missing. The available hematological features do not provide sufficient information to screen for this specific deficiency."
"3A10.3,3A10,Familial pseudohyperkalaemia",,,"Familial pseudohyperkalaemia is characterized by elevated serum potassium levels without true hyperkalemia. Key features such as serum potassium measurements are missing, which are essential for screening and assessing this condition."
"3A20.3,3A20,Paroxysmal cold haemoglobinuria",,,"Paroxysmal cold hemoglobinuria is characterized by hemolysis due to cold exposure, typically requiring specific tests such as direct Coombs test, urine hemoglobin, and possibly cold agglutinins, which are not included in the available features."
"3A21.0,3A21,Paroxysmal nocturnal haemoglobinuria",,,"Key features such as flow cytometry results for CD55 and CD59 expression, which are critical for diagnosing Paroxysmal Nocturnal Hemoglobinuria (PNH), are not available. Additionally, the absence of direct measures of hemolysis (e.g., haptoglobin, reticulocyte count) limits the ability to screen for this condition effectively."
"3A21.2,3A21,Haemolytic uraemic syndrome",,,"Key features such as renal function tests (e.g., creatinine clearance), specific markers for hemolysis (e.g., haptoglobin, reticulocyte count), and direct measures of thrombotic microangiopathy are missing, which are essential for screening hemolytic uremic syndrome."
"3A51.0,3A51,Sickle cell trait",,,"Screening for sickle cell trait typically requires hemoglobin electrophoresis or genetic testing to identify the presence of the HbS allele. The available features do not include any specific tests for hemoglobin variants or genetic markers, which are essential for accurate screening."
"3A51.3,3A51,Compound heterozygous sickling disorders without crisis",,,"Key signals for screening compound heterozygous sickling disorders, such as hemoglobin electrophoresis or genetic testing for sickle cell mutations, are missing. The available features do not provide sufficient specificity or sensitivity for effective screening."
"3A51.4,3A51,Compound heterozygous sickling disorders with crisis",,,"Key signals for screening sickle cell disorders, such as hemoglobin electrophoresis or genetic testing for hemoglobin variants, are missing. While some hematological parameters are available, they do not provide sufficient specificity or sensitivity for screening compound heterozygous sickling disorders."
"3A51.7,3A51,High affinity haemoglobin",,,"Key signals for high affinity hemoglobin disorders, such as specific hemoglobin electrophoresis results or genetic testing for hemoglobin variants, are not available in the listed features."
"3A72.01,3A72,Hereditary syndromic sideroblastic anaemia",,,"Key signals for hereditary syndromic sideroblastic anemia, such as specific iron studies (e.g., serum ferritin, transferrin saturation), genetic testing for mutations, and bone marrow examination for ringed sideroblasts, are missing. The available features do not provide sufficient information to screen or assess likelihood effectively."
"3A91,3A91,Congenital methaemoglobinaemia",,,"Key signals for congenital methaemoglobinaemia, such as methemoglobin levels or specific genetic markers, are not included in the available features."
"3A92,3A92,Hereditary methaemoglobinaemia",,,"Key signals for hereditary methaemoglobinaemia, such as methemoglobin levels or specific genetic markers, are not included in the available features. The listed hematological parameters do not provide sufficient information to screen for this condition."
"3A93,3A93,Acquired methaemoglobinaemia",,,"Key signals for screening acquired methemoglobinemia, such as methemoglobin levels or specific exposure history (e.g., drugs or chemicals), are not included in the available features."
"3B10.0,3B10,Haemophilia A",,,"Key signals for screening Haemophilia A, such as factor VIII activity levels or specific genetic testing for mutations in the F8 gene, are not included in the available features."
"3B10.1,3B10,Hereditary factor VIII deficiency with anti-factor VIII inhibitor",,,"Key signals for screening hereditary factor VIII deficiency with anti-factor VIII inhibitor, such as specific factor VIII activity assays and inhibitor testing, are not available in the listed features."
"3B10.Y,3B10,Other specified hereditary factor VIII deficiency",,,"Key signals for screening hereditary factor VIII deficiency, such as specific factor VIII activity assays or genetic testing for mutations in the F8 gene, are not available in the listed features."
"3B10.Z,3B10,""Hereditary factor VIII deficiency, unspecified""",,,"Key signals for screening hereditary factor VIII deficiency, such as specific factor VIII activity levels or genetic testing for mutations in the F8 gene, are not available in the listed features."
"3B11.0,3B11,Haemophilia B",,,"Key signals for screening Haemophilia B, such as specific factor IX activity levels or genetic testing for mutations in the F9 gene, are not available in the listed features."
"3B11.Y,3B11,Other specified hereditary factor IX deficiency",,,"Key signals for screening hereditary factor IX deficiency, such as specific coagulation factor assays (e.g., factor IX activity), are missing. The available features do not include relevant hematological parameters or genetic testing necessary for effective screening."
"3B11.Z,3B11,""Hereditary factor IX deficiency, unspecified""",,,"Key signals for screening hereditary factor IX deficiency, such as specific coagulation factor assays (e.g., factor IX activity), are missing. The available features do not include relevant hematological parameters or genetic markers necessary for effective screening."
"3B12,3B12,Von Willebrand disease",,,"Von Willebrand disease screening typically requires specific tests for von Willebrand factor levels and activity, as well as factor VIII levels, which are not included in the available features. The listed hematological parameters do not provide sufficient information to assess the likelihood of this bleeding disorder."
"3B13,3B13,Haemophilia C",,,"Key signals for screening Haemophilia C, such as specific factor XI activity levels or genetic testing for mutations in the F11 gene, are not available in the listed features."
"3B14.0,3B14,Hereditary deficiency of factor I",,,"Key signals for screening hereditary deficiency of factor I, such as specific factor I activity assays or genetic testing, are not available in the listed features. The available hematological parameters do not provide sufficient information to assess this condition."
"3B14.1,3B14,Hereditary factor X deficiency",,,"Key signals for hereditary factor X deficiency, such as specific coagulation factor assays (e.g., factor X activity), are missing. The available features do not include any coagulation parameters necessary for screening or assessing bleeding disorders."
"3B14.2,3B14,Combined deficiency of vitamin K-dependent clotting factors",,,"Key signals for screening combined deficiency of vitamin K-dependent clotting factors, such as prothrombin time (PT) and specific vitamin K levels, are missing. The available features do not include coagulation parameters necessary for assessing this condition."
"3B14.Z,3B14,Other inherited coagulation factor deficiency with bleeding tendency, unspecified",,,"Key signals for inherited coagulation factor deficiencies, such as specific factor levels (e.g., Factor VIII, Factor IX), are missing. The available features do not include coagulation studies or specific bleeding disorder markers necessary for screening."
"3B15,3B15,Inherited coagulation factor deficiency without bleeding tendency",,,"Key signals for inherited coagulation factor deficiencies, such as specific factor assays (e.g., Factor VIII, Factor IX levels), are missing. The available features do not provide the necessary hematological parameters to assess coagulation factor levels or function."
"3B20,3B20,Disseminated intravascular coagulation",,,"Key signals for disseminated intravascular coagulation (DIC) such as fibrinogen levels, D-dimer, and specific coagulation factors are missing. The available features do not provide sufficient information to assess coagulation status or the presence of DIC."
"3B21.0,3B21,Haemorrhage due to thrombin inhibitor other than heparin",,,"Key signals such as specific coagulation parameters (e.g., thrombin time, anti-Xa levels) and clinical history of anticoagulant use are missing, which are essential for screening and assessing the likelihood of hemorrhage due to thrombin inhibitors."
"3B21.1,3B21,Haemorrhage due to factor Xa inhibitor",,,"Key signals for screening hemorrhage due to factor Xa inhibitors, such as specific coagulation tests (e.g., anti-Xa levels, PT/INR, aPTT), are missing. The available features do not provide sufficient information to assess bleeding risk or anticoagulation status."
"3B21.Y,3B21,Haemorrhagic disorder due to other specified circulating anticoagulants",,,"Key signals such as specific coagulation factor levels, presence of circulating anticoagulants, or specific tests for bleeding disorders are missing. The available features do not provide the necessary information to assess the likelihood of hemorrhagic disorders due to circulating anticoagulants."
"3B21.Z,3B21,Haemorrhagic disorder due to unspecified circulating anticoagulants",,,"Key signals for screening hemorrhagic disorders due to circulating anticoagulants, such as specific coagulation tests (e.g., PT, aPTT, specific inhibitor assays), are missing. The available features do not provide sufficient information to assess bleeding risk or anticoagulant presence."
"3B22,3B22,Acquired haemophilia",,,"Acquired hemophilia is characterized by the presence of inhibitors against clotting factors, particularly factor VIII. Key diagnostic features such as specific factor assays (e.g., factor VIII activity, inhibitor testing) and clinical bleeding history are essential for screening, which are not included in the available NHANES features."
"3B2Y,3B2Y,Other specified haemorrhagic diseases due to acquired coagulation factor defects",,,"Key signals for screening acquired coagulation factor defects, such as specific factor assays (e.g., Factor VIII, Factor IX levels) and functional assays (e.g., PT, aPTT), are missing. The available features do not provide sufficient information to assess coagulation status or factor deficiencies."
"3B50.0,3B50,Congenital alpha-2 antiplasmin deficiency",,,"Key signals for screening congenital alpha-2 antiplasmin deficiency, such as specific functional assays for alpha-2 antiplasmin levels or genetic testing, are missing. The available features do not provide the necessary information to assess the likelihood of this deficiency."
"3B50.1,3B50,Congenital plasminogen activator inhibitor type 1 deficiency",,,"Key signals for screening congenital plasminogen activator inhibitor type 1 deficiency, such as specific genetic testing or functional assays to measure plasminogen activator inhibitor levels, are not available in the listed features."
"3B50.Y,3B50,Other specified inherited fibrinolytic defects",,,"Key signals for inherited fibrinolytic defects, such as specific fibrinolytic enzyme activity assays (e.g., plasminogen levels, tissue plasminogen activator), are not available in the listed features."
"3B50.Z,3B50,Inherited fibrinolytic defects, unspecified",,,"Inherited fibrinolytic defects require specific assays to evaluate fibrinolytic activity, such as plasminogen levels, fibrinogen levels, and specific clotting factor assays, which are not included in the available features."
"3B51,3B51,Acquired fibrinolytic defects",,,"Acquired fibrinolytic defects require specific markers such as D-dimer levels or fibrinogen levels to assess fibrinolytic activity, which are not included in the available features."
"3B60.0,3B60,Hereditary vascular purpura",,,"Key signals for hereditary vascular purpura, such as specific genetic markers or tests for von Willebrand factor levels, are not included in the available features."
"3B60.1,3B60,Acquired vascular purpura",,,"Key signals for acquired vascular purpura, such as specific platelet function tests, coagulation profiles, or markers of vascular integrity, are missing. The available features do not provide sufficient information to assess the likelihood of this condition."
"3B61.0,3B61,Hereditary thrombophilia",,,"Key signals for hereditary thrombophilia, such as specific genetic markers (e.g., Factor V Leiden, Prothrombin mutation) and functional assays (e.g., activated protein C resistance), are not available in the listed features."
"3B61.00,3B61,Hyperhomocysteinaemia",,,"Hyperhomocysteinaemia is primarily assessed through serum homocysteine levels, which are not included in the available features. Without this key analyte, screening for the condition is not feasible."
"3B61.0Y,3B61,Other specified hereditary thrombophilia",,,"Key signals for hereditary thrombophilia, such as genetic markers (e.g., factor V Leiden, prothrombin mutation) and specific coagulation tests (e.g., protein C, protein S, antithrombin levels), are missing from the available features."
"3B61.0Z,3B61,Hereditary thrombophilia, unspecified",,,"Key signals for hereditary thrombophilia, such as genetic testing for specific mutations (e.g., Factor V Leiden, Prothrombin gene mutation) and functional assays (e.g., activated protein C resistance), are not available in the listed features."
"3B61.1,3B61,Acquired thrombophilia",,,"Key signals for acquired thrombophilia, such as specific coagulation factor levels (e.g., antiphospholipid antibodies, protein C, protein S, and antithrombin), are missing. The available features do not provide sufficient information to assess thrombotic risk or diagnose acquired thrombophilia."
"3B61.Y,3B61,Other specified thrombophilia",,,"Key signals for thrombophilia screening, such as genetic markers (e.g., Factor V Leiden, prothrombin mutation) and specific coagulation tests (e.g., antiphospholipid antibodies, protein C/S levels), are missing from the available features."
"3B61.Z,3B61,Thrombophilia, unspecified",,,"Key signals for thrombophilia screening, such as specific coagulation factor levels (e.g., Factor V Leiden, prothrombin mutation), antiphospholipid antibodies, and genetic testing, are not available in the listed features."
"3B62.00,3B62,Alpha-granule diseases",,,"Key signals for alpha-granule diseases, such as specific platelet function tests or genetic markers, are missing. The available features do not provide sufficient information to screen or assess the likelihood of this disease."
"3B62.1,3B62,Bleeding diathesis due to thromboxane synthesis deficiency",,,"Key signals for screening thromboxane synthesis deficiency, such as platelet function tests (e.g., platelet aggregation studies) and specific biochemical markers related to thromboxane metabolism, are missing. The available features do not provide sufficient information to assess bleeding diathesis related to thromboxane synthesis."
"3B62.3,3B62,Dense granule disease",,,"Dense granule disease is a type of platelet storage pool disorder, which typically requires specific platelet function tests or genetic testing to diagnose. The available NHANES features do not include any specific tests for platelet function or granule content, making screening for this condition not feasible."
"3B62.4,3B62,Alpha-delta dense granule deficiency",,,"Alpha-delta dense granule deficiency is characterized by specific platelet function abnormalities and granule deficiencies, which require specialized tests such as platelet aggregation studies and electron microscopy for diagnosis. The available NHANES features do not include any specific tests for platelet function or granule content, making screening for this condition not feasible."
"3B64.13,3B64,Alloimmune thrombocytopenia",,,"Alloimmune thrombocytopenia requires specific tests for platelet antibodies or HLA typing, which are not included in the available features. The available features do not provide sufficient information to screen or assess the likelihood of this condition."
"3B64.14,3B64,Thrombotic thrombocytopenic purpura",,,"Key signals for thrombotic thrombocytopenic purpura (TTP) include ADAMTS13 activity and inhibitor levels, as well as specific clinical features like schistocytes on a blood smear. The available NHANES features do not include these essential tests or clinical indicators necessary for screening or likelihood assessment of TTP."
"3B65,3B65,""Thrombotic microangiopathy, not elsewhere classified""",,,"Key signals for thrombotic microangiopathy, such as ADAMTS13 activity, anti-ADAMTS13 antibodies, and specific imaging studies, are missing. The available features do not provide sufficient information to screen or assess likelihood effectively."
"3B6Y,3B6Y,""Other specified coagulation defects, purpura or other haemorrhagic or related conditions""",,,"Key signals for screening coagulation defects, such as specific coagulation factor levels (e.g., factor VIII, factor IX), platelet function tests, or genetic markers, are missing. The available features do not provide sufficient information to assess coagulation status or bleeding risk effectively."
"3B80.0,3B80,Splenomegaly in storage diseases",,,"Key signals for screening splenomegaly in storage diseases, such as imaging studies (e.g., ultrasound, CT scan) and specific biochemical markers (e.g., enzyme levels related to specific storage diseases), are missing. The available features do not provide sufficient information to assess the likelihood of splenomegaly effectively."
"3B81.0,3B81,Tumour-like conditions of spleen",,,"Key diagnostic signals such as imaging studies (e.g., ultrasound, CT scan) or specific biomarkers related to splenic tumors are not available in the listed features, making screening for tumor-like conditions of the spleen infeasible."
"3B81.1,3B81,Postsurgical asplenia",,,"Key signals for assessing postsurgical asplenia, such as specific immunological markers (e.g., antibody responses, vaccination status) and clinical history of infections, are missing. The available features do not provide sufficient information to screen for the complications associated with asplenia."
"3B81.2,3B81,Atrophy of spleen",,,"Key signals for assessing splenic atrophy, such as imaging studies (e.g., ultrasound, CT scan) or specific biomarkers related to splenic function, are missing. The available hematological features do not provide sufficient information to screen for atrophy of the spleen."
"3B81.3,3B81,Nontraumatic laceration or rupture of spleen",,,"Key features such as imaging studies (e.g., ultrasound or CT scan) to identify splenic laceration or rupture are missing. Additionally, clinical signs of splenic injury (e.g., abdominal pain, hypotension) and specific laboratory tests (e.g., hemoglobin drop, lactate levels) that indicate splenic rupture are not available."
"3B81.4,3B81,Splenosis",,,"Key signals for diagnosing splenosis, such as imaging studies (e.g., ultrasound, CT scan) or specific genetic markers, are not available in the listed features. The available hematological parameters do not provide sufficient information to screen for splenosis effectively."
"3B81.5,3B81,Splenic cyst or pseudocyst",,,"Key imaging features (e.g., ultrasound or CT scans) necessary for diagnosing splenic cysts or pseudocysts are not available in the listed NHANES features."
"3B81.50,3B81,Pseudocyst of spleen",,,"Key imaging studies (e.g., ultrasound or CT scan) and specific laboratory tests (e.g., serum amylase or lipase) that are essential for diagnosing and screening pseudocysts of the spleen are not available in the listed features."
"3B81.51,3B81,Epithelial cyst of spleen",,,"Epithelial cysts of the spleen typically require imaging studies (e.g., ultrasound, CT scan) for diagnosis, which are not included in the available NHANES features. The listed features primarily assess hematological and biochemical parameters, which do not provide the necessary information for screening or likelihood assessment of this specific condition."
"3B81.5Y,3B81,Other specified splenic cyst",,,"Key imaging features (e.g., ultrasound or CT scans) necessary for diagnosing splenic cysts are missing, as well as specific laboratory markers that could indicate splenic pathology."
"3B81.5Z,3B81,""Splenic cyst, unspecified""",,,"Key imaging features (e.g., ultrasound or CT scans) necessary for diagnosing splenic cysts are not available, making screening for this condition infeasible."
"3B81.6,3B81,Infarction of spleen",,,"Key signals for screening splenic infarction, such as imaging studies (e.g., ultrasound or CT scan) and specific clinical history (e.g., sickle cell disease, thrombosis), are missing. The available hematological features do not provide sufficient information to assess the likelihood of splenic infarction."
"3B81.7,3B81,Infection of spleen",,,"Key signals for screening splenic infections, such as imaging studies (ultrasound, CT) or specific serological tests for pathogens, are missing. The available features primarily assess hematological parameters and do not provide sufficient information to screen for splenic infections."
"3B81.71,3B81,Abscess of spleen",,,"Key diagnostic signals for splenic abscess, such as imaging studies (e.g., ultrasound, CT scan) and clinical signs of infection, are missing. While some hematological parameters (e.g., white blood cell count) may suggest infection, they are insufficient for screening or triaging splenic abscess specifically."
"3B81.7Y,3B81,Other specified infection of spleen",,,"Key signals for screening infections of the spleen, such as imaging studies (e.g., ultrasound, CT scan) or specific serological tests for pathogens, are missing. The available features primarily assess hematological parameters and do not provide sufficient information to screen for splenic infections."
"3B81.8,3B81,Torsion of spleen",,,"Torsion of the spleen typically requires imaging studies (e.g., ultrasound or CT scan) for diagnosis, which are not included in the available features. The listed hematological features do not provide sufficient information to screen for this condition."
"3B81.9,3B81,Fibrosis of spleen",,,"Key signals for screening fibrosis of the spleen, such as imaging studies (e.g., ultrasound, CT scan) or specific biomarkers (e.g., liver function tests indicating portal hypertension), are not available in the listed features."
"3B81.A,3B81,Perisplenitis",,,"Perisplenitis typically requires imaging studies (e.g., ultrasound or CT scan) to assess splenic inflammation, which are not available in the listed features. Additionally, specific clinical history and physical examination findings are crucial for diagnosis, which cannot be captured through the available laboratory measurements alone."
"3B81.C,3B81,Chronic congestive splenomegaly",,,"Chronic congestive splenomegaly requires imaging studies (e.g., ultrasound, CT) or specific biomarkers related to splenic function and portal hypertension, which are not available in the listed features."
"3B81.Y,3B81,Other specified acquired disorders of spleen",,,"Key signals for assessing splenic disorders, such as imaging studies (e.g., ultrasound, CT scan) or specific laboratory tests (e.g., splenic function tests, genetic markers), are missing. The available features primarily assess blood parameters and do not provide sufficient information to screen for acquired disorders of the spleen."
